Abstract P2-01-26: Carboplatin added to neoadjuvant chemotherapy in a randomized phase II study: Complex DNA based biomarkers predict response in hormone receptor positive and triple negative breast cancer

作者
Olav Engebraaten,Marianne Lislerud Smebye,Arne V. Pladsen,Øystein Garred,Elin Borgen,Eivind Valen Egeland,Mads Haugland Haugen,Maria Aanesland Dahle,Gunhild Mari Mælandsmo,Eivind J. Hovig,Sigve Nakken,Anne Alexandra Østgaard,Inger Riise Bergheim,Ellen Schlichting,Helle Kristine Skjerven,Anne‐Lise Børresen‐Dale,Erik Wist,Bjørn Naume,Hege Elisabeth Giercksky Russnes,Ole Christian Lingjærde
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:31 (12_Supplement): P2-01
标识
DOI:10.1158/1557-3265.sabcs24-p2-01-26
摘要

Abstract Background: Carboplatin (Cb) improves treatment efficacy among patients with triple negative breast cancer (TNBC). However, not all patients need additional chemotherapy and the benefit for patients with hormone receptor positive breast cancer (HR+BC) has not been extensively investigated. Tumor-specific copy number alterations may predict sensitivity to DNA damaging agents such as Cb. The I-BCT-1 (Improved Breast Cancer Therapy – 1) study was designed to discover biomarkers associated with treatment response, in patients with high-risk HR+BC and TNBC. Methods: Patients with HER2 negative high risk (by Ki67, ER/PgR and/or grade) cT2-4 tumors and no distant metastases were randomized 1:1 to paclitaxel (80 mg/m2, Q1W) alone or in combination with Cb (AUC6 Q3W), for 12 weeks, followed by four cycles of EC90 (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2; Q3W). Tumor sampling was performed before treatment start, along the treatment, and at surgery, but only data related to initial sampling is reported here. Complex biomarkers based on somatic copy number alterations (the complex arm-wise aberration index (CAAI), loss of heterozygosity (LOH) and homologous recombination deficiency (HRD)) status were determined based on exome sequencing data. The influence of Cb on chemotherapy delivery and toxicities was analysed. Results: In the 187 patients randomized, the median follow-up was 4.7 years (range 1.0 – 7.9 years). Among the TNBC patients (n=72), the pCR rate was 69% in the Cb group (n=35) vs. 43% in the control group (n=37; p = 0.036). For HR+BC patients (n=115), the pCR rate was 15% in the Cb group vs. 11% in the control group (n.s.), but the fraction of these patients with residual cancer burden (RCB) 0 or 1 increased from 16 to 35% by Cb treatment (p = 0.033). For TNBC patients, event-free survival (EFS) was significantly improved in the Cb group compared to the control group (p=0.017, HR 0.24, 95% CI 0.07-0.86). For HR+BC patients, no improvement in EFS was observed (p=0.684, HR 1.19, 95% CI 0.52-2.71). The proportion of patients with serious adverse events was 42.1% in the Cb group vs. 18.5% in the control group (p<0.001). In TNBC patients receiving Cb, high CAAI was associated with an improved pCR rate (p=0.029). HRD has earlier been investigated as a marker for several DNA targeted therapies, including Cb, but no significant difference in pCR was found in the TNBC patients according to HRD status. In HR+BC patients receiving Cb, the pCR rate was significantly higher in patients with HRD tumors vs. patients with non HRD tumors (p=0.002; not associated with germline BRCA status). In TNBC patients with a low genomic fraction of LOH, the treatment outcome was better in the Cb group than in the control group (p=0.005). In TNBC patients who did not receive Cb, high genomic fraction of LOH was associated with a good prognosis. This was validated in an independent dataset of TNBC patients (n=144, p=0.034), indicating a limited additional effect of Cb for patients with tumor harbouring a high fraction of LOH. Conclusion: In TNBC patients, Cb improves the pCR rate and EFS. In HRBC patients, Cb improves the favorable outcome with RCB 0/1, but not EFS. The results suggest that different complex DNA based biomarkers predict response in hormone receptor positive and triple negative breast cancer: HRD should be further investigated as a predictive marker for Cb benefit in hormone receptor positive patients, while genomic fraction of LOH may be an important marker for treatment selection in triple negative breast cancer patients. Clinical trial identification: EudraCT number: 2013 – 004418 – 17 / ClinicalTrials.gov ID NCT02546232 Citation Format: Olav Engebraaten, Marianne Lislerud Smebye, Arne Valebjørg Pladsen, Øystein Garred, Elin Borgen, Eivind Valen Egeland, Mads Haugland Haugen, Maria Aanesland Dahle, Gunhild Mari Mælandsmo, Eivind Hovig, Sigve Nakken, Anne Alexandra Østgaard, Inger Riise Bergheim, Ellen Schlichting, Helle Skjerven, Anne-Lise Børresen Dale, Erik Wist, Bjørn Naume, Hege Russnes, Ole Christian Lingjærde. Carboplatin added to neoadjuvant chemotherapy in a randomized phase II study: Complex DNA based biomarkers predict response in hormone receptor positive and triple negative breast cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P2-01-26.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhao完成签到,获得积分0
刚刚
xxxx发布了新的文献求助10
1秒前
1秒前
月白发布了新的文献求助10
1秒前
1秒前
Kunpeng发布了新的文献求助30
1秒前
秋秋完成签到,获得积分10
2秒前
yaoji发布了新的文献求助10
2秒前
dh发布了新的文献求助10
3秒前
zyx完成签到,获得积分10
3秒前
余如龙完成签到,获得积分10
3秒前
阿豆阿豆发布了新的文献求助10
5秒前
情怀的应助被丁驰采纳,获得10
6秒前
零的孤心俱乐部完成签到,获得积分10
6秒前
机智小馒头完成签到,获得积分10
7秒前
8秒前
9秒前
小小怪发布了新的文献求助10
9秒前
打打的应助被哈哈哈哈采纳,获得10
10秒前
等待冰淇淋关注了科研通微信公众号
10秒前
10秒前
zww发布了新的文献求助10
10秒前
12秒前
12秒前
leiyuekai完成签到 ,获得积分10
13秒前
科研通AI6.3的应助被biochen采纳,获得10
14秒前
还等雨落的应助被洋芋大侠采纳,获得10
14秒前
科研通AI6.2的应助被ZZ采纳,获得10
15秒前
15秒前
1234发布了新的文献求助10
15秒前
科研通AI6.4的应助被Frank采纳,获得10
15秒前
15秒前
叶远望完成签到 ,获得积分10
17秒前
姜昊彤发布了新的文献求助10
18秒前
moon驳回了jjn的应助
18秒前
18秒前
Jane完成签到,获得积分10
18秒前
这名字完成签到,获得积分10
19秒前
20秒前
yt发布了新的文献求助10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192871
求助须知:如何正确求助?哪些是违规求助? 9579281
关于积分的说明 21864358
捐赠科研通 7792445
什么是DOI,文献DOI怎么找? 3437059
关于科研通互助平台的介绍 2560639
邀请新用户注册赠送积分活动 2483928